Boston Scientific’s (BSX) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of Boston Scientific (NYSE:BSX) in a research report report published on Monday,Benzinga reports. Royal Bank Of Canada currently has a $115.00 target price on the medical equipment provider’s stock.

A number of other research firms have also recently issued reports on BSX. TD Cowen cut their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Finally, Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Boston Scientific Stock Down 1.2%

NYSE:BSX opened at $62.01 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock has a 50 day moving average of $75.78 and a 200-day moving average of $89.84. The firm has a market capitalization of $92.15 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. Boston Scientific has a 52 week low of $61.24 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The business’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.50% of the stock is owned by company insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Gerber Kawasaki Wealth & Investment Management boosted its stake in Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC raised its position in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares in the last quarter. Claret Asset Management Corp raised its position in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares during the last quarter. Finally, Scotia Capital Inc. boosted its position in shares of Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after purchasing an additional 104 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and key secondary endpoints for the WATCHMAN FLX versus NOACs — clinical data supports the WATCHMAN franchise and stroke-prevention positioning, which is bullish for long-term device revenues. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Boston Scientific completed its acquisition of Valencia Technologies — expands product pipeline/technology footprint (supports tuck‑in growth and cross‑sell opportunities). Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Additional clinical/data wins and study support for intravascular ultrasound (IVUS) in PCI underscore minimally invasive care leadership — a structural growth thesis for cardiovascular devices. Boston Scientific study backs use of intravascular ultrasound in PCI
• Neutral Sentiment: Some analysts reiterated positive views (RBC, Needham, Raymond James earlier reaffirmations), and long‑term bull pieces highlight durable growth — supports case for recovery if execution stabilizes. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Negative Sentiment: Raymond James downgraded the stock and cut estimates amid concerns about U.S. electrophysiology trends and Watchman uptake, which triggered a sharp share decline and hurt near‑term sentiment. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Unusually large put‑option volume today (put buying jumped ~205%) signals elevated short‑term hedging or bearish bets from traders, adding downside pressure. Options activity report
• Negative Sentiment: Multiple law firms have filed or solicited investors for securities‑fraud class actions tied to allegations about disclosure of electrophysiology volumes and related issues — legal risk and potential litigation costs are headline negatives for sentiment. Bronstein class action notice

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.